Product Overview
[Drug Name]
Generic Name: Bisoprolol Fumarate Tablets
Trade Name: Bosu
English Name: Bisoprolol Fumarate Tablets
Chinese Pinyin: Fumasuan Bisuoluoer Pian
[Ingredients]
Bisoprolol fumarate.
[Appearance]
White tablets.
[Indications]
For the treatment of essential hypertension and angina pectoris.
[Dosage and Administration]
Oral administration. Once daily, starting dose 2.5 mg, maximum daily dose not exceeding 10 mg. Please follow your doctor's advice. No dosage adjustment is required for patients with mild or moderate hepatic or renal insufficiency. For patients with advanced renal insufficiency (creatinine clearance <20 ml/min) or severe hepatic insufficiency, the daily dose should not exceed 10 mg.
[Adverse Reactions]
1. Mild fatigue, chest tightness, dizziness, bradycardia, drowsiness, palpitations, headache, and lower limb edema may occur initially, but these symptoms will subside or disappear spontaneously with continued medication. 2. In rare cases, gastrointestinal disturbances (diarrhea, constipation, nausea, abdominal pain) and skin reactions (such as erythema and itching) may occur. 3. Occasionally, a significant drop in blood pressure, a slow pulse, or atrioventricular conduction disturbances may occur. 4. Occasionally, a tingling sensation or cold extremities may occur. In rare cases, muscle weakness, painful muscle cramps, and decreased tearing may occur. 5. Patients with intermittent claudication or Raynaud's phenomenon may experience worsening of symptoms during the initial treatment phase, and those with pre-existing myocardial dysfunction may also experience aggravation. 6. Increased airway resistance may occasionally occur. 7. In elderly patients with diabetes, glucose tolerance may be impaired, masking the symptoms of hypoglycemia (such as a rapid heart rate).
[Contraindications]
1. Shock, atrioventricular conduction disorders (second- and third-degree atrioventricular block), sick sinus syndrome, sinoatrial block, bradycardia (less than 50/min), hypotension, bronchial asthma, and advanced peripheral circulatory disorders. 2. Adrenal adenoma (pheochromocytoma). This product should only be taken after taking an alpha-receptor blocker.
[Precautions]
1. Diabetic patients with large blood sugar fluctuations and acidosis should use with caution. 2. Use with caution in patients with pulmonary insufficiency or severe hepatic and renal insufficiency. 3. When interrupting treatment, the dose should be gradually reduced daily. A dose reduction is often required when used in combination with other antihypertensive drugs. 4. If an overdose causes bradycardia or hypotension, this product must be discontinued. If necessary, the following medications may be used alone or continuously: atropine 0.5mg-2.0mg IV, iprostatol slow IV infusion in appropriate amounts, and glucagon 1mg-5mg (or 1mg-10mg). 5. Due to the antihypertensive effect of this drug, the patient's ability to drive or operate machinery may be impaired, especially when first taking it, when switching medications, or when taken with alcohol. However, this does not directly affect a person's reaction time.
[Use in Special Populations]
Precautions for Children: This drug should not be used.
Precautions for Pregnancy and Breastfeeding: When taking this drug during pregnancy, to prevent bradycardia, hypotension, and hypoglycemia in the neonate, discontinue use of this drug 72 hours before the due date. If continued use is necessary, the neonate should be closely monitored for 48 to 72 hours after delivery.
Precautions for Elderly: Please follow your doctor's advice.
[Drug Interactions]
1. The antihypertensive effect of this drug is enhanced when used in combination with other antihypertensive drugs. 2. This drug can slow the heart rate when used in combination with reserpine, methyldopa, clonidine, or chlorpheniramine. 3. When used in combination with reserpine, wait several days after stopping this drug before discontinuing reserpine. 4. The antihypertensive effect of this drug can be enhanced when used in combination with nifedipine. 5. Patient monitoring is required when co-administered with verapamil, diltiazem-type calcium channel blockers, or other antiarrhythmic drugs, as hypotension, bradycardia, and other potential side effects may occur.
[Pharmacological Action]
This drug is a selective β1-adrenergic receptor blocker. It has no intrinsic sympathomimetic activity or membrane stabilizing effects. Experiments in various animal models have shown that its affinity for β1-receptors is 11-34 times greater than for β2-receptors, and its selectivity for β1 receptors is four times that of the similar drug atenolol. This drug has a long duration of action (over 24 hours), provides excellent symptom control with continuous use, and exhibits no tolerance. It has minimal respiratory side effects and has no observed effects on fat metabolism.
[Storage] Store in a dark, airtight container.
[Specification] 5mg x 10 tablets
[Packaging] Box
[Validity Period] 36 months
[Approval Number] National Medicine Standard H10970082
[Manufacturer] Company Name: Beijing Huasu Pharmaceutical Co., Ltd.
